-
Featured Authors
-
Archives
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Business and Investments
Latest From Business and Investments
The BTK buyout
Remember this BTK post we wrote back in February of 2010? Well, we thought it was time to revisit the makeup of the BTK index (NYSE Arca Biotechnology Index). Five of the 20 companies that comprised the index in February of last year have either been acquired or are facing acquisition. That means 25% of the entire index has been snapped up in a little over a year (Table 1). Millipore (MIL) and OSI Pharmaceuticals (OSIP) acquired in 2010 by Merck KGaA and Astellas, respectively, have already Read More >
Take a look at our New Partnering Guide
We’ve just finished creating a new guide to the BIO One-on-One Partnering System! Step-by-Step Instructions for Partnering Success. It’s designed to be an easy overview of how get started with the system, with a few tips and tricks along the way. You can find it whenever you visit the WWGD blog, too, by visiting the Resources page. If you have specific questions or need help with partnering, please leave a comment, or feel free to Read More >
BIO Europe Spring – State of the Biotech Industry
BIO Industry Analysis provided opening remarks at BIO Europe Spring in Milan, Italy, this morning. Dr. John Craighead shared the highlights of BIO’s latest industry update: click here for the slides in pdf format.
Anitbody Deals Peaked in 2007
Antibody and antibody-like scaffold molecules have been on the pharma licensing radar for some time. The pharma business development interest in these drug candidates stems largely from the targeted mechanisms of action, structural uniqueness of the molecules, strong IP, and portfolio diversification benefits. To analyze deal trends in this niche area of biotechnology, we screened the Windhover/Elsevier Strategic Transactions Database for “Biotechnology” deals, with “Antibody” or “Large Molecule” identifiers, from 2007-2010. From this initial list, Read More >
A Partner in Partnering: BIO and the China Healthcare Investment Conference
If you’re attending the China Healthcare Investment Conference this month, you’ll probably notice something familiar. BIO has partnered with the Lychee Group to use the One-on-One Partnering System during their event! The event focuses on the most influential Chinese and global thought leaders to promote the development of the Chinese healthcare market, and all attendees will now be able to send requests, schedule meetings, and connect with one another in private meetings. As with all Read More >
